Metabolomics profiling of acute myelogenous leukemia patients to identify systemic differences associated with in vitro sensitivity to SYK inhibitors.

Metabolomics · 2026 · PMC13090287 · PMID 41995902

Europe PMC DOI

hedged sentence

0.3800

closest p · 7.6× alpha

0.3800

boldest claim

The sentences

did not reach statistical significancep = 0.380not close (p > 0.1)

Although a trend towards more CD34 positive and NPM1 -wt patients in the high sensitivity group, this did not reach statistical significance whether analyzed separately for SYK-selective inhibitors (CD34: p = 0.380, and NPM1: p = 0.63, Fisher’s exact test).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.